LLS Co-Pay Assistance Fund Hits $200 million

The Leukemia & Lymphoma Society is announcing that it has now raised more than $200 million in funding for its Co-Pay Assistance Program since its inception in 2007.

The program

This LLS program provides patient support for prescription drug co-pays as well as health insurance premiums for blood cancer patients who meet certain income requirements.

Also eligible are patients with:

  • Private insurance
  • Medicare beneficiaries under Medicare Part B and/or Medicare Plan D, Medicare Supplementary Health Insurance and Medicare Advantage

Since 2007 the program has helped more than 36,000 patients.

John Walter, LLS president and CEO, said in a statement:

Receiving a diagnosis of a blood cancer can be overwhelming for a patient, and such devastating news can be compounded by an inability to afford the treatments. LLS's Co-Pay Assistance Program helps alleviate this burden for eligible patients and their families. LLS exists not only to find cures, but also to ensure access to the best available therapies for all blood cancer patients, and helping patients afford their treatments is a critical part of our mission.

To find out more

Interested patients and caregivers can learn more about this program by visiting lls.org/copay or they can call 877-LLS-COPAY.

Source: LLS

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap